Found 23 articles for: "Vitiligo"
Vitiligo Successfully Treated With Roflumilast Cream 0.3%
July 2026 | Volume 25 | Issue 7 | Case Reports | 662 | Copyright © July 2026
Vitiligo is an autoimmune cutaneous depigmenting disorder that can have significant psychological impacts on affected patients, posing a burden to daily life, which can be even more apparent in p...
Read MoreDelays in Medical Care Among Skin of Color Melanoma Patients: A Population-Based Study
April 2026 | Volume 25 | Issue 4 | Features | 391 | Copyright © April 2026
Association Between Topical Ruxolitinib Treatment and Psychiatric Outcomes in Adults With Vitiligo
April 2026 | Volume 25 | Issue 4 | Features | 388 | Copyright © April 2026
Halo Seborrheic Keratosis in a Patient of Color With Vitiligo
January 2026 | Volume 25 | Issue 1 | Case Reports | 95 | Copyright © January 2026
A 73-year-old woman with Fitzpatrick skin type V presented with a long-standing brownish-black, three-tone macule on the right anterior thigh that developed a sharply demarcated depigmented halo....
Read MoreNational Institutes of Health Funding for Vitiligo Research: Trends from 1985 to 2024
December 2025 | Volume 24 | Issue 12 | Features | 1260 | Copyright © December 2025
Background: The National Institutes of Health (NIH) funds a multitude of dermatology research. This study examines NIH funding for vitiligo studies and highlights key trends.Read MoreMaximizing a Focused Vitiligo Patient Visit: A Practical Approach
December 2025 | Volume 24 | Issue 12 | Features | 1256 | Copyright © December 2025
The Current Landscape of Vitiligo Treatment Centers
August 2025 | Volume 24 | Issue 8 | Editorials | e51 | Copyright © August 2025
Readability and Content Characterization of Online Reading Materials for Individuals With Vitiligo
April 2025 | Volume 24 | Issue 4 | Editorials | 419 | Copyright © April 2025
Disparities in Alopecia Areata and Vitiligo FDA-Approved Therapies in Medicaid Formularies
March 2025 | Volume 24 | Issue 3 | Editorials | e17 | Copyright © March 2025
Co-occurring Melanoma in an Active Area of Vitiligo in Skin of Color
February 2025 | Volume 24 | Issue 2 | Case Reports | 205 | Copyright © February 2025
The association between vitiligo and melanoma is complex. While the incidence of vitiligo in patients with melanoma is higher, the risk for the reverse, ie, the development of melanoma in a patie...
Read MoreA Review of the Vitiligo Literature to Standardize Expression of Disease Severity
October 2024 | Volume 23 | Issue 10 | Original Article | 842 | Copyright © October 2024
Background: The literature on vitiligo is heterogeneous with limited standardization in vitiligo disease severity reporting.Objectives: The IDEOM Vitiligo Workgroup ...
Read MoreRepresentation of Skin of Color in Social Media Discussions on Melasma, Keloids, and Vitiligo
July 2024 | Volume 23 | Issue 7 | Original Article | 510 | Copyright © July 2024
Background: The prevalence of social media as a source of medical information has grown substantially in recent years, especially for skin conditions disproportionately affecting...
Read MoreRacial and Ethnic Diversity in Vitiligo Clinical Trials: A Retrospective Cross-Sectional Study Assessing Demographic Reporting of Participants
July 2024 | Volume 23 | Issue 7 | Editorials | e164 | Copyright © July 2024
Background: While the prevalence of vitiligo is similar across racial and ethnic groups, the effects of vitiligo vary by demographic group, culture, and skin color, with darker-s...
Read MoreThe Pediatric Dermatologist's View of Pediatric Vitiligo
February 2024 | Volume 23 | Issue 2 | Editorials | e77 | Copyright © February 2024
Background: No guidelines exist for pediatric vitiligo.Objective: To identify practice patterns of pediatric dermatologists treating vitiligo....
Read MoreA Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo
July 2023 | Volume 22 | Issue 7 | Original Article | 664 | Copyright © July 2023
Background: This article describes the clinical trial, safety, and efficacy of ruxolitinib 1.5% cream or repigmentation in patients with vitiligo.Data Sources: A sys...
Read MoreShining a Light on Vitiligo and Associated Comorbidities: What Is the Evidence?
April 2023 | Volume 22 | Issue 4 | Features | 428 | Copyright © April 2023
Citation: Desai S, McCormick E, Sodha P, et al. Shining a light on the vitiligo and associated comorbidities: What is the evidence? J Drugs Dermatol. 2023;22(4):428-430. doi:10.36849...
Read MoreRefractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
December 2022 | Volume 21 | Issue 12 | Case Reports | 1366 | Copyright © December 2022
Background: In the last several years, oral tofacitinib has become an increasingly utilized off-label treatment option for immune-mediated skin conditions such as alopecia areata (AA)...
Read MoreA Potential Alternative Treatment for Vitiligo: An Observational Study on Tacrolimus 0.3% Lotion
December 2022 | Volume 21 | Issue 12 | Features | 1370 | Copyright © December 2022
Vitiligo is a complex multifactorial disorder of depigmentation affecting 0.5 to 2% of the world's population without specific gender or racial prevalence.1 Though no treatments are FDA app...
Read MoreSocial Media Platforms as a Resource for Vitiligo Support
October 2022 | Volume 21 | Issue 10 | Editorials | 1135 | Copyright © October 2022
Social media use among dermatology patients is ubiquitous, with estimates of over 80% of patients using social media to learn about their dermatologic conditions. Vitiligo is an autoimmune disease lea...
Read MoreShort and Long-Term Outcomes of 308-nm Laser for Pediatric Vitiligo
July 2022 | Volume 21 | Issue 7 | Original Article | 773 | Copyright © July 2022
Pediatric vitiligo is often challenging to treat. Children with vitiligo experience stigma, bullying, and emotional distress. The long-term outcome of therapeutics used to treat pediatric vitiligo has...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
